Skip to content

Tribute Pharmaceuticals Canada Inc.: 10-Q/A filed 2011-08-22

What Tribute Pharmaceuticals Canada Inc. reported in its quarterly report amendment filed 2011-08-22 (fiscal Q2 2011): 30 published measures, 96 facts as tagged in accession 0001354488-11-003018.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-Q/A (quarterly report amendment)
Filed
2011-08-22
Fiscal period
fiscal Q2 2011
Accession
0001354488-11-003018 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Tribute Pharmaceuticals Canada Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-06-306,612,796USD
At 2010-12-317,280,594USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2011-06-30634,036USD
At 2010-12-311,132,123USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-06-305,978,760USD
At 2010-12-316,148,471USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-06-303,453,867USD
At 2010-12-314,352,285USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-04-01 to 2011-06-3058,405USD91
2011-01-01 to 2011-06-30-244,490USD181
2010-04-01 to 2010-06-30360,776USD91
2010-01-01 to 2010-06-30113,238USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-242,085USD91
2011-01-01 to 2011-06-30-852,246USD181
2010-04-01 to 2010-06-30-21,948USD91
2010-01-01 to 2010-06-30-334,367USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-5,008USD91
2011-01-01 to 2011-06-30-5,008USD181
2010-04-01 to 2010-06-30-40,290USD91
2010-01-01 to 2010-06-30-262,142USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2011-04-01 to 2011-06-301,072,705USD91
2011-01-01 to 2011-06-301,706,748USD181
2010-04-01 to 2010-06-301,255,811USD91
2010-01-01 to 2010-06-301,833,688USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-21,684USD91
2011-01-01 to 2011-06-30-21,684USD181
2010-04-01 to 2010-06-3069,000USD91
2010-01-01 to 2010-06-3069,000USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-20,545USD91
2011-01-01 to 2011-06-30-24,488USD181
2010-04-01 to 2010-06-30-43,123USD91
2010-01-01 to 2010-06-30-260,359USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2011-06-30-4,097,299USD
At 2011-03-31-4,155,704USD
At 2010-12-31-3,852,809USD
At 2010-06-30-4,265,279USD
At 2010-03-31-4,626,055USD
At 2009-12-31-4,378,517USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2011-06-301,520,851USD
At 2010-12-311,568,729USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-04-01 to 2011-06-3027,262USD91
2011-01-01 to 2011-06-3090,998USD181
2010-04-01 to 2010-06-3017,443USD91
2010-01-01 to 2010-06-3051,390USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-04-01 to 2011-06-3055,042USD91
2011-01-01 to 2011-06-30-251,344USD181
2010-04-01 to 2010-06-30359,166USD91
2010-01-01 to 2010-06-30125,423USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-06-304,935,354USD
At 2010-12-315,572,578USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-06-30352,943USD
At 2010-12-31915,300USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2011-06-30175,707USD
At 2010-12-31236,420USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2011-06-30567,116USD
At 2010-12-31493,370USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-04-01 to 2011-06-30755,870USD91
2011-01-01 to 2011-06-301,525,164USD181
2010-04-01 to 2010-06-30615,928USD91
2010-01-01 to 2010-06-301,223,791USD181

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2011-06-30725,466USD
At 2010-12-31611,676USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2011-04-01 to 2011-06-30810,922USD91
2011-01-01 to 2011-06-301,273,820USD181
2010-04-01 to 2010-06-30975,094USD91
2010-01-01 to 2010-06-301,349,214USD181

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2011-04-01 to 2011-06-30261,783USD91
2011-01-01 to 2011-06-30432,928USD181
2010-04-01 to 2010-06-30280,717USD91
2010-01-01 to 2010-06-30484,474USD181

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2011-04-01 to 2011-06-30698,946USD91
2011-01-01 to 2011-06-301,403,002USD181
2010-04-01 to 2010-06-30592,585USD91
2010-01-01 to 2010-06-301,160,517USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-04-01 to 2011-06-3020,093USD91
2011-01-01 to 2011-06-3033,771USD181
2010-04-01 to 2010-06-309,683USD91
2010-01-01 to 2010-06-3035,954USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-06-3024,610,042shares
At 2010-12-3124,585,040shares

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2011-06-30156,591USD
At 2010-12-31139,287USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2011-06-30154,635USD
At 2010-12-3199,433USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2011-04-01 to 2011-06-3058,405USD91
2011-01-01 to 2011-06-30-244,490USD181
2010-04-01 to 2010-06-30360,776USD91
2010-01-01 to 2010-06-30113,238USD181

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2011-04-01 to 2011-06-300USD91
2011-01-01 to 2011-06-300USD181
2010-04-01 to 2010-06-30-29,300USD91
2010-01-01 to 2010-06-30-29,300USD181

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2011-04-01 to 2011-06-300USD91
2011-01-01 to 2011-06-300USD181
2010-04-01 to 2010-06-3029,300USD91
2010-01-01 to 2010-06-3029,300USD181

Inspect the source

Entity
Tribute Pharmaceuticals Canada Inc. / CIK 0001159019
Captured
SEC response SHA-256
580713a84aa79c7c06f7641b783696cf8e0676bb71dd55f93cd67e6d441393a2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001159019.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))